(b) Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs. Table 123: Clinical Evidence Summary: Varma 1999: Long Pharmacist-led clinic (MDT pharm) vs Primary care (1 control) >6 months for low risk HF Outcomes No of Participants (studies) Follow up Quality of the evidence (GRADE) Relative effect Anticipated absolute effects Risk with primary care Risk difference with MDT pharm (95% CI) Referral and approach to care Chronic Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: Outcomes No of Participants (studies) Follow up Quality of the evidence (GRADE) Relative effect Anticipated absolute effects Risk with primary care Risk difference with MDT pharm (95% CI) VERY LOWa, b due to risk of bias, imprecision ratio (from 20 fewer to 481 fewer) VERY LOWa, b due to risk of bias, imprecision (from 106 fewer to 263 more) Quality of life Minnesota LWHFQ, lower=better. Scale from: 0 to 105. VERY LOWa, b due to risk of bias, imprecision The mean MLWHFQ final score in the control groups was The mean quality of life in the intervention groups was 6.40 lower (better) Taking prescribed medication Self-report LOWa due to risk of bias (from 67 fewer to 172 more) Taking prescribed medication Automated measure VERY LOWa, b due to risk of bias, imprecision (from 15 fewer to 1000 more) (a) Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias. (b) Downgraded by one increment as confidence interval crosses one MID or two increments as confidence interval crosses both MID. 